<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744976</url>
  </required_header>
  <id_info>
    <org_study_id>IVUS-0216</org_study_id>
    <nct_id>NCT02744976</nct_id>
  </id_info>
  <brief_title>Coronary Artery Disease Progression in Patients With Prediabetes</brief_title>
  <official_title>Coronary Artery Disease Progression by iMap Intravascular Ultrasound Analysis in Patients With Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pauls Stradins Clinical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pauls Stradins Clinical University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prediabetes is a disorder of glucose metabolism that reflects the natural history of&#xD;
      progression from normoglycaemia to type 2 diabetes mellitus. Patients with prediabetes have&#xD;
      impaired glucose regulation caused by insulin resistance (IR). IR in patients undergoing&#xD;
      percutaneous coronary intervention (PCI) is associated with coronary artery remodeling and&#xD;
      coronary plaque vulnerability by intravascular ultrasound (IVUS) analysis. In stent&#xD;
      restenosis after bare metal and drug-eluting stent implantation more frequently is observed&#xD;
      in patients with high fasting-insulin levels and IR. Although IR has a significant role in&#xD;
      the progression of atherosclerosis in prediabetic patients, the importance of managing&#xD;
      prediabetes is often under-appreciated by clinicians. To date, no pharmacological treatment&#xD;
      has been officially approved for prediabetes. According to American Diabetes Association&#xD;
      recommendations, metformin is the only drug that could be considered in the treatment of&#xD;
      prediabetic patients with a high risk of developing diabetes. Metformin is a safe and&#xD;
      inexpensive glucose lowering drug that attenuates mortality and future cardiovascular events&#xD;
      in patients with type 2 diabetes as well as the progression of atherosclerosis in&#xD;
      non-diabetic animal models. This study was designed to analyze coronary plaque&#xD;
      characteristics by iMAP IVUS in patients with and without prediabetes undergoing PCI and to&#xD;
      evaluate the impact of metformin treatment on coronary plaque characteristics in prediabetic&#xD;
      patients at 24 month follow up.&#xD;
&#xD;
      The study hypothesis is that more pronounced coronary atherosclerosis progression as well as&#xD;
      in-stent neointimal hyperplasia will be observed in patients with prediabetes. Metformin&#xD;
      treatment attenuates the progression of atherosclerosis in patients with prediabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing PCI and IVUS pullback for the target vessel will be enrolled in a&#xD;
      prospective study. Before PCI and at 24 month follow up fasting blood will be collected for&#xD;
      glucose, HbA1c, C peptide, lipid profile assessment. Patients' baseline demographic&#xD;
      characteristics, medical history, and procedural data will be collected during the index&#xD;
      hospitalization and at 24 month follow up. Patients will be divided in groups according to&#xD;
      HbA1c - control group (HbA1c&lt;5.7) and prediabetic patients (HbA1c 5.7-6.4). PCI will be&#xD;
      performed in accordance with the guidelines. After successful treatment of the culprit lesion&#xD;
      IVUS will be done. Following PCI and IVUS patients with prediabetes will be randomly assigned&#xD;
      in groups either receiving metformin at a dose of 2000 mg once daily plus standard lifestyle&#xD;
      recommendations or standard lifestyle recommendations only. Intravascular ultrasound analysis&#xD;
      will be repeated 24 months after the initial PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage plaque volume change over 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in plaque volume in 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Culprit lesion in-stent restenosis</measure>
    <time_frame>24 months</time_frame>
    <description>Neointimal hyperplasia at 24 month follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque tissue component percentage change over 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage change in necrotic, fibrotic, lipidic and calcific tissue volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of glycemic parameters with plaque characteristics</measure>
    <time_frame>At index hospitalization and follow up (24 months)</time_frame>
    <description>Correlation of glycemic parameters with plaque characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque volume change in metformin vs non-metformin treated patients over 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Plaque volume change in metformin vs non-metformin treated patients over 24 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Atherosclerosis</condition>
  <condition>Prediabetic State</condition>
  <arm_group>
    <arm_group_label>Prediabetes, metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HbA1c 5.7-6.4 receiving metformin and lifestyle recommendations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prediabetes, lifestyle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with HbA1c 5.7-6.4 receiving lifestyle recommendations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months</description>
    <arm_group_label>Prediabetes, metformin</arm_group_label>
    <other_name>Glucophage extended release (XR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle recommendations</intervention_name>
    <description>Standard lifestyle recommendations</description>
    <arm_group_label>Prediabetes, lifestyle</arm_group_label>
    <arm_group_label>Prediabetes, metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age â‰¥18 and &lt;75 years;&#xD;
&#xD;
          -  patients with stable coronary artery disease referred to PCI in an artery suitable for&#xD;
             IVUS pullback;&#xD;
&#xD;
          -  signed informed consent before PCI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cardiac or non-cardiac illness with life expectancy of less than two years;&#xD;
&#xD;
          -  failure to advance the IVUS catheter through the culprit lesion;&#xD;
&#xD;
          -  acute coronary syndrome&#xD;
&#xD;
          -  congestive heart failure (New York Heart Association (NYHA) classification stage&#xD;
             III-IV)&#xD;
&#xD;
          -  diabetes mellitus&#xD;
&#xD;
          -  chronic kidney disease&#xD;
&#xD;
          -  previous PCI in the target vessel&#xD;
&#xD;
          -  heavily calcified vessels&#xD;
&#xD;
          -  allergy to metformin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Latvia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pauls Stradins Clinical University Hospital</investigator_affiliation>
    <investigator_full_name>Karlis Trusinskis</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Prediabetes</keyword>
  <keyword>Intravascular ultrasound</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

